Lysophosphatidic Acid in Oncogenesis

溶血磷脂酸在肿瘤发生中的作用

基本信息

  • 批准号:
    7876906
  • 负责人:
  • 金额:
    $ 23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-08-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

Revised Abstract Lysophosphatidic acid (LPA), a naturally occurring lysophospholipid, is a ligand of at least five G protein-coupled receptors (LPA15). The LPA13 receptors are members of the endothelial cell differentiation gene (Edg) family and couple to Gi, Gq, and G12/13 subunits of G proteins to activate an array of intracellular signaling cascades, leading to cytoskeleton rearrangement, cell proliferation, survival, and migration. Overexpression of the Edg LPA receptors and upregulation of LPA production via LysoPLD/autotaxin (AIX) are common abnormalities found in various human cancers. However, studies of oncogenic roles of LPA have been hampered by lack of in vivo evidence or an animal model to show involvement of LPA signals in tumor development. Recently, p2y9/GPR23/LPA4 of the purinergic receptor family and a related GPR92/LPA5 are identified as novel LPA receptors. These two receptors are structurally distant from the Edg LPA1..3 receptors and couple to Gq, GI 2/13 and Gs subunits. The biological functions of LPA4 and LPA5 receptors, particularly their roles in cancer have not been previously studied. We recently disrupted the Ipa4 gene by targeted deletion in mice. Although the LPA4 is not required for embryonic development and fertility, we observed a dramatic increase in development of spontaneous tumors in Ipa4 mutant mice. The tumors include malignant lymphoma, lung adenocarcinoma, high-grade sarcoma, leiomyosarcoma, plasmacytoma and pilomatrixoma. The wide spectrum of tumors found in these mice not only provides direct evidence for aberrant LPA signaling in tumorigenesis but also raises the possibility that LPA4 acts as a tumor suppressor. Our preliminary results further suggest that lack of LPA4 sensitizes cells to LPA-induced cell motility and activation of specific intracellular pathways. We therefore hypothesize that, in contrast to the Edg LPA receptors, LPA4 negatively regulates specific LPA signaling pathways and oncogenic activity of LPA. As a result, the lack of LPA4 predisposes mice to tumor development. The hypothesis will be tested through the following three Specific Aims: Aim 1. To determine the role of LPA4 in tumor suppression in mice; Aim 2. To elucidate the functions of LPA4 in LPA signal transduction; Aim 3. To evaluate whether deletion of LPA4 increases susceptibility of mice to chemical carcinogenesis We will determine tumor incidence, histotypes and metastasis rate of tumors in two independent lines of Ipa4 knockout mice in Aim 1. We will take advantage of the LPA4-deficient cells and other knockdown or overexpression approaches to investigate the biological functions of LPA4 in the regulation of LPA signal transduction and cellular responses (Aim 2). In Aim 3, the tumor suppressive function of LPA4 will be further explored by examining the susceptibility of LPA4 null mice to chemical carcinogens. These proposed studies together will establish the role of LPA4 in tumor suppression and may lead to identification of novel anticancer targets.
修订摘要 溶血磷脂酸 (LPA) 是一种天然存在的溶血磷脂,是至少 五个 G 蛋白偶联受体 (LPA15)。 LPA13 受体是内皮细胞的成员 细胞分化基因 (Edg) 家族并与 G 蛋白的 Gi、Gq 和 G12/13 亚基偶联, 激活一系列细胞内信号级联,导致细胞骨架重排,细胞 增殖、生存和迁移。 Edg LPA 受体的过度表达和上调 通过 LysoPLD/autotaxin (AIX) 产生的 LPA 是多种疾病中常见的异常现象。 人类癌症。然而,由于缺乏相关证据,LPA 致癌作用的研究受到了阻碍。 体内证据或动物模型显示 LPA 信号参与肿瘤发展。 最近,嘌呤能受体家族的p2y9/GPR23/LPA4和相关的 GPR92/LPA5 被鉴定为新型 LPA 受体。这两种受体在结构上 远离 Edg LPA1..3 受体并与 Gq、GI 2/13 和 Gs 亚基偶联。这 LPA4 和 LPA5 受体的生物学功能,特别是它们在癌症中的作用尚未明确 之前已经研究过。我们最近通过在小鼠中进行定向删除来破坏 Ipa4 基因。 虽然 LPA4 不是胚胎发育和生育所必需的,但我们观察到 Ipa4 突变小鼠中自发性肿瘤的发展显着增加。肿瘤 包括恶性淋巴瘤、肺腺癌、高级肉瘤、平滑肌肉瘤、 浆细胞瘤和毛基质瘤。在这些小鼠中发现的广泛肿瘤不仅 为肿瘤发生中异常的 LPA 信号传导提供了直接证据,但也提出了 LPA4 可能充当肿瘤抑制因子。我们的初步结果进一步表明 LPA4 的缺乏会使细胞对 LPA 诱导的细胞运动和特定细胞内的激活变得敏感 途径。因此,我们假设,与 Edg LPA 受体相比,LPA4 负调节特定的 LPA 信号通路和 LPA 的致癌活性。作为 因此,缺乏 LPA4 会使小鼠容易患肿瘤。假设将是 通过以下三个具体目标进行测试: 目的1. 确定LPA4在小鼠肿瘤抑制中的作用; 目的2.阐明LPA4在LPA信号转导中的功能; 目标 3. 评估 LPA4 缺失是否会增加小鼠对化学物质的敏感性 致癌作用 我们将确定两种肿瘤的发病率、组织型和转移率 目标 1 中 Ipa4 敲除小鼠的独立品系。我们将利用 LPA4 缺陷的优势 细胞和其他敲低或过度表达方法来研究生物学 LPA4 在 LPA 信号转导和细胞反应调节中的功能(目标 2)。 在目标 3 中,将通过检查 LPA4 的肿瘤抑制功能来进一步探讨 LPA4 缺失小鼠对化学致癌物的易感性。这些拟议的研究将共同 确定 LPA4 在肿瘤抑制中的作用并可能导致新型抗癌药物的鉴定 目标。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Large scale purification and characterization of recombinant human autotaxin/lysophospholipase D from mammalian cells.
从哺乳动物细胞中大规模纯化重组人自分泌运动因子/溶血磷脂酶 D 并对其进行表征。
  • DOI:
    10.5483/bmbrep.2010.43.8.541
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Song,Yuanda;Dilger,Emily;Bell,Jessica;Barton,WilliamA;Fang,Xianjun
  • 通讯作者:
    Fang,Xianjun
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

XIANJUN FANG其他文献

XIANJUN FANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('XIANJUN FANG', 18)}}的其他基金

Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
脂肪酸β-氧化代谢重编程以改善癌症免疫治疗
  • 批准号:
    10599149
  • 财政年份:
    2019
  • 资助金额:
    $ 23万
  • 项目类别:
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
脂肪酸β-氧化代谢重编程以改善癌症免疫治疗
  • 批准号:
    10361537
  • 财政年份:
    2019
  • 资助金额:
    $ 23万
  • 项目类别:
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
溶血磷脂酸对卵巢癌脂肪生成的调节
  • 批准号:
    8333999
  • 财政年份:
    2011
  • 资助金额:
    $ 23万
  • 项目类别:
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
溶血磷脂酸对卵巢癌脂肪生成的调节
  • 批准号:
    8177055
  • 财政年份:
    2011
  • 资助金额:
    $ 23万
  • 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
  • 批准号:
    7241458
  • 财政年份:
    2004
  • 资助金额:
    $ 23万
  • 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
  • 批准号:
    6774357
  • 财政年份:
    2004
  • 资助金额:
    $ 23万
  • 项目类别:
Lysophosphatidic Acid in Oncogenesis
溶血磷脂酸在肿瘤发生中的作用
  • 批准号:
    7735592
  • 财政年份:
    2004
  • 资助金额:
    $ 23万
  • 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
  • 批准号:
    6919241
  • 财政年份:
    2004
  • 资助金额:
    $ 23万
  • 项目类别:
Lysophospholipid in Neovascularization in Ovarian Cancer
溶血磷脂在卵巢癌新血管形成中的作用
  • 批准号:
    7104837
  • 财政年份:
    2004
  • 资助金额:
    $ 23万
  • 项目类别:

相似海外基金

Cerebrovascular endothelial cilia in the pathogenesis and therapy of Alzheimer's disease
脑血管内皮纤毛在阿尔茨海默病发病机制和治疗中的作用
  • 批准号:
    10575082
  • 财政年份:
    2023
  • 资助金额:
    $ 23万
  • 项目类别:
Mechanistic investigation into Frizzled-2 signaling for treatment of Osteogenesis Imperfecta
Frizzled-2 信号传导治疗成骨不全症的机制研究
  • 批准号:
    10680236
  • 财政年份:
    2023
  • 资助金额:
    $ 23万
  • 项目类别:
Age-related mechanisms of altered tendon structure and function
肌腱结构和功能改变的年龄相关机制
  • 批准号:
    10678395
  • 财政年份:
    2023
  • 资助金额:
    $ 23万
  • 项目类别:
Novel mechanisms of muscle and bone loss with HIV infection, antiretroviral therapy, and aging.
HIV 感染、抗逆转录病毒治疗和衰老导致肌肉和骨质流失的新机制。
  • 批准号:
    10696502
  • 财政年份:
    2023
  • 资助金额:
    $ 23万
  • 项目类别:
Breathprinting as a window into gut microbiome chemoecology
呼吸印迹是了解肠道微生物组化学生态学的窗口
  • 批准号:
    10512356
  • 财政年份:
    2022
  • 资助金额:
    $ 23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了